US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

A biomarker panel for IPF may identify RA patients at higher risk for ILD, supporting biological overlap between IPF and ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

Several factors — but not older age — increased infection risk with the use of non-TNF biologics following first-line ...

Treatment with TNF-α inhibitors may be safer than IL-6 inhibitors in terms of cardiovascular outcomes when managing patients with RA and T2D.

Yuflyma (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications – adolescent ...

Adherence to healthy dietary patterns, including anti-inflammatory and Mediterranean diets, is associated with a lower risk of developing rheumatoid arthritis (RA), according to study findings ...

A machine learning model can use patient-reported data and remote therapeutic monitoring to accurately assess low disease ...

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...

ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...

Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children, affecting thousands of young patients across the United States. For some, it comes with a hidden and dangerous ...